Literature DB >> 11195418

NCCN Practice Guidelines for Breast Cancer.

R W Carlson1, B O Anderson, W Bensinger, C E Cox, N E Davidson, S B Edge, W B Farrar, L J Goldstein, W J Gradishar, A S Lichter, B McCormick, L M Nabell, E C Reed, S M Silver, M L Smith, G Somlo, R Theriault, J H Ward, E P Winer, A Wolff.   

Abstract

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. In many situations, the patient and physician have the responsibility to jointly explore and ultimately select the most appropriate option from among the available alternatives. With rare exception, the evaluation, treatment, and follow-up recommendations contained within these guidelines were based largely on the results of past and present clinical trials. However, there is not a single clinical situation in which the treatment of breast cancer has been optimized with respect to either maximizing cure or minimizing toxicity and disfigurement. Therefore, patient and physician participation in prospective clinical trials allows patients not only to receive state-of-the-art cancer treatment but also to contribute to the improvement of treatment of future patients.

Entities:  

Mesh:

Year:  2000        PMID: 11195418

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  20 in total

Review 1.  The LIVESTRONG Survivorship Center of Excellence Network.

Authors:  Charles L Shapiro; Mary S McCabe; Karen L Syrjala; Debra Friedman; Linda A Jacobs; Patricia A Ganz; Lisa Diller; Marci Campell; Kathryn Orcena; Alfred C Marcus
Journal:  J Cancer Surviv       Date:  2009-01-24       Impact factor: 4.442

2.  Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer.

Authors:  Xianglin L Du; Cynthia Osborne; James S Goodwin
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

3.  Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.

Authors:  Isabelle Bedrosian; Chung-Yuan Hu; George J Chang
Journal:  J Natl Cancer Inst       Date:  2010-02-25       Impact factor: 13.506

4.  HER2 evaluation and its impact on breast cancer treatment decisions.

Authors:  K A B Goddard; S Weinmann; K Richert-Boe; C Chen; J Bulkley; C Wax
Journal:  Public Health Genomics       Date:  2011-05-03       Impact factor: 2.000

5.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Authors:  Roman Rouzier; Radhika Rajan; Peter Wagner; Kenneth R Hess; David L Gold; James Stec; Mark Ayers; Jeffrey S Ross; Peter Zhang; Thomas A Buchholz; Henry Kuerer; Marjorie Green; Banu Arun; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-24       Impact factor: 11.205

6.  Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia.

Authors:  Gery P Guy; Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Kevin C Ward
Journal:  Health Serv Res       Date:  2014-12-10       Impact factor: 3.402

Review 7.  Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.

Authors:  Suzanne Eccles; Lenaic Paon; Jonathan Sleeman
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

Review 8.  Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.

Authors:  Miriam Sharpe; Stephanie E Easthope; Gillian M Keating; Harriet M Lamb
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  The Evolution of Axillary Staging in Breast Cancer.

Authors:  Roshni Rao
Journal:  Mo Med       Date:  2015 Sep-Oct

10.  Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.

Authors:  Xianglin L Du; Charles R Key; Cynthia Osborne; Jonathan D Mahnken; James S Goodwin
Journal:  Ann Intern Med       Date:  2003-01-21       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.